Global Antibiotic Research and Development Partnership
room 15 Chemin Camille-Vidart | 1202 Geneva | Switzerland
arrow_back See all Activities

Sexually Transmitted Infections

IATI Identifier:

Published on IATI
  • date_range Jan 01, 2017
  • autorenew Implementation (Status)

Gonorrhoea is caused by the bacteria Neisseria gonorrhoeae, which has progressively developed resistance to globally recommended treatments and has been identified by the World Health Organization as a priority infection urgently requiring new antibiotics. To address the lack of effective drugs, the Global Antibiotic Research and Development Partnership (GARDP) is developing a new treatment for gonorrhoea and is working to ensure it is available to everyone who needs it, wherever they live.

more_horiz
Sectors:

  • Medical research

Participating Organisations

UK - Department of Health and Social Care (DHSC) Government Funding
German Federal Ministry of Education and Research Government Funding
German Federal Ministry of Health Government Funding
Japanese Ministry of Health, Labour & Welfare Government Funding
The Grand Duchy Of Luxembourg Government Funding
The Netherlands Ministry of Health, Welfare and Sport Government Funding
Federal Office of Public Health Government Funding
South African Medical Research Council Other Public Sector Funding
Global Antibiotic Research and Development Partnership Foundation Implementing

Transaction

Transaction Value Provider
Receiver 		Type Date
Not Available Provider N/A Receiver N/A
date_range
Not Available Provider N/A Receiver N/A
date_range
Not Available Provider N/A Receiver N/A
date_range
Not Available Provider N/A Receiver N/A
date_range
Not Available Provider N/A Receiver N/A
date_range
Not Available Provider N/A Receiver N/A
date_range
Not Available Provider N/A Receiver N/A
date_range
Not Available Provider N/A Receiver N/A
date_range
Not Available Provider N/A Receiver N/A
date_range
Not Available Provider N/A Receiver N/A
date_range
Not Available Provider N/A Receiver N/A
date_range
Not Available Provider N/A Receiver N/A
date_range
Not Available Provider N/A Receiver N/A
date_range
Not Available Provider N/A Receiver N/A
date_range
Not Available Provider N/A Receiver N/A
date_range
Not Available Provider N/A Receiver N/A
date_range
Not Available Provider N/A Receiver N/A
date_range
Not Available Provider N/A Receiver N/A
date_range
Not Available Provider N/A Receiver N/A
date_range
Not Available Provider N/A Receiver N/A
date_range
Not Available Provider N/A Receiver N/A
date_range
Not Available Provider N/A Receiver N/A
date_range
Not Available Provider N/A Receiver N/A
date_range
Not Available Provider N/A Receiver N/A
date_range
Not Available Provider N/A Receiver N/A
date_range
Not Available Provider N/A Receiver N/A
date_range
Not Available Provider N/A Receiver N/A
date_range
Not Available Provider N/A Receiver N/A
date_range
Not Available Provider N/A Receiver N/A
date_range
Not Available Provider N/A Receiver N/A
date_range
Not Available Provider N/A Receiver N/A
date_range
Not Available Provider N/A Receiver N/A
date_range
Not Available Provider N/A Receiver N/A
date_range
Not Available Provider N/A Receiver N/A
date_range
Not Available Provider N/A Receiver N/A
date_range
Not Available Provider N/A Receiver N/A
date_range
Not Available Provider N/A Receiver N/A
date_range
Not Available Provider N/A Receiver N/A
date_range
Not Available Provider N/A Receiver N/A
date_range
Not Available Provider N/A Receiver N/A
date_range
Not Available Provider N/A Receiver N/A
date_range

Budget

4,795,993 USD
  • 4,150,572 EUR (Valued at Oct 06, 2021)
    date_range Jan 01, 2020 - Dec 31, 2020
access_time Updated on Nov 24, 2021 09:30:03